IN2014MN02367A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02367A
IN2014MN02367A IN2367MUN2014A IN2014MN02367A IN 2014MN02367 A IN2014MN02367 A IN 2014MN02367A IN 2367MUN2014 A IN2367MUN2014 A IN 2367MUN2014A IN 2014MN02367 A IN2014MN02367 A IN 2014MN02367A
Authority
IN
India
Prior art keywords
blys
stimulating factor
blys antibody
lymphocyte stimulating
biopharmaceutics
Prior art date
Application number
Inventor
Bo Chen
Hui Feng
Hongbing Shu
Original Assignee
Wuhan Therasource Biosciences Inc
Shanghai Union Biopharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Therasource Biosciences Inc, Shanghai Union Biopharm Co Ltd filed Critical Wuhan Therasource Biosciences Inc
Publication of IN2014MN02367A publication Critical patent/IN2014MN02367A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the field of biopharmaceutics. Disclosed is an anti BLyS antibody. The anti BLyS antibody specifically targets BLyS can combine with a B lymphocyte stimulating factor and can inhibit the combination of the B lymphocyte stimulating factor with the receptor BR3 FC thereof. Also provided are uses of the anti BLyS antibody in the preparation of drugs for preventing and/or treating diseases such as systemic lupus erythematosus caused by the excessive proliferation of B cells.
IN2367MUN2014 2012-05-22 2013-05-22 IN2014MN02367A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201210160474.3A CN103421113B (en) 2012-05-22 2012-05-22 Anti- BLyS antibody
PCT/CN2013/076074 WO2013174264A1 (en) 2012-05-22 2013-05-22 Anti-blys antibody

Publications (1)

Publication Number Publication Date
IN2014MN02367A true IN2014MN02367A (en) 2015-08-14

Family

ID=49623127

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2367MUN2014 IN2014MN02367A (en) 2012-05-22 2013-05-22

Country Status (8)

Country Link
US (1) US9828423B2 (en)
EP (2) EP3792280A3 (en)
JP (1) JP6006404B2 (en)
CN (1) CN103421113B (en)
IN (1) IN2014MN02367A (en)
RU (1) RU2613422C2 (en)
WO (1) WO2013174264A1 (en)
ZA (1) ZA201408955B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3838923B1 (en) 2012-08-24 2024-05-01 The Regents of The University of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CN104045713B (en) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 The monoclonal antibody of anti-Blys a kind of and pharmaceutical composition containing the antibody
CN104804091B (en) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 Nano antibody for resisting B cell growth stimulating factor and application
CN104804092B (en) * 2014-01-29 2018-03-27 天津胜发生物技术有限公司 A kind of nano antibody of anti-B cell growth-stimulating factor and application thereof
CN104804090B (en) * 2014-01-29 2018-03-27 普瑞金（深圳）生物技术有限公司 Nano antibody for resisting B cell growth stimulating factor and application
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN104628856A (en) * 2015-01-23 2015-05-20 中国人民解放军军事医学科学院放射与辐射医学研究所 Anti-BLyS single-chain antibody as well as preparation method and use thereof
CN105061596B (en) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 The monoclonal antibody and its application of human B lymphocyte stimulating factor
CN106916224B (en) * 2015-12-28 2021-03-23 中国人民解放军军事医学科学院放射与辐射医学研究所 Monoclonal antibody for resisting B lymphocyte stimulating factor and its prepn and use
SG11201811559WA (en) 2016-06-27 2019-01-30 Univ California Cancer treatment combinations
WO2018006824A1 (en) * 2016-07-06 2018-01-11 上海开拓者生物医药有限公司 Blys antibody, preparation method therefor and application thereof
US11623953B2 (en) * 2017-02-27 2023-04-11 Caerus Therapeutics, Inc. Antibody constructs and methods of treating cancer
EP3918326A4 (en) * 2019-01-31 2022-04-20 Siemens Healthcare Diagnostics, Inc. Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof
CN112111461B (en) * 2020-08-17 2022-08-30 浙江正熙生物医药有限公司 Method for constructing monoclonal antibody high-yield strain cell working library by single cell sorting
WO2022223028A1 (en) * 2021-04-23 2022-10-27 上海君实生物医药科技股份有限公司 Anti-blys antibody, pharmaceutical composition thereof and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) * 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
PT939804E (en) * 1996-10-25 2005-11-30 Human Genome Sciences Inc ALPHA NEUTROQUIN
KR101287395B1 (en) * 2000-06-16 2014-11-04 휴먼 게놈 사이언시즈, 인코포레이티드 Antibodies that immunospecifically bind to BLyS
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
WO2003055979A2 (en) 2001-11-16 2003-07-10 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
US20020150579A1 (en) * 2002-01-10 2002-10-17 Kimberly Robert P. B lymphocyte stimulator (BLyS) as a marker in management of systemic lupus erythematosus
CN1168831C (en) * 2002-05-24 2004-09-29 张志方 Construction of recombinant human B lymphocyte stimulating factor expression vector, DNA immunopreparation of monoclonal antibody and use thereof
RU2005141541A (en) * 2003-06-05 2006-06-27 Дженентек, Инк. (Us) COMBINED THERAPY OF B-CELL DISORDERS
KR20070001880A (en) * 2003-10-20 2007-01-04 바이오겐 아이덱 엠에이 인코포레이티드 Therapeutic regimens for baff antagonists
CN101851291B (en) * 2010-02-09 2011-10-26 中国人民解放军第四军医大学 Heavy chain and light chain variable regions of anti-human BAFF monoclonal antibody

Also Published As

Publication number Publication date
US20150259409A1 (en) 2015-09-17
CN103421113B (en) 2018-01-19
ZA201408955B (en) 2015-12-23
BR112014025651A2 (en) 2017-07-04
EP2853543B1 (en) 2020-09-02
RU2613422C2 (en) 2017-03-16
EP2853543A4 (en) 2016-03-30
EP2853543A8 (en) 2015-05-13
EP2853543A1 (en) 2015-04-01
JP6006404B2 (en) 2016-10-12
RU2014133410A (en) 2016-07-10
JP2015517505A (en) 2015-06-22
WO2013174264A1 (en) 2013-11-28
US9828423B2 (en) 2017-11-28
EP3792280A3 (en) 2021-07-21
EP3792280A2 (en) 2021-03-17
CN103421113A (en) 2013-12-04

Similar Documents

Publication Publication Date Title
IN2014MN02367A (en)
IN2015KN00414A (en)
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2015011132A (en) Polycyclic estrogen receptor modulators and uses thereof.
NI201500059A (en) BRUTON TYROSINE KINASE INHIBITORS
IN2014MN01642A (en)
MX2016003129A (en) Combination therapy of antibodies against human csf-1r and antibodies against human pd-l1.
EA201690618A1 (en) BLUTON TYROSINKINASE INHIBITORS
BR112014026952A2 (en) aminopyrimidine pyrazole derivatives as modulators lrrk2
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2015015221A (en) Tolerogenic synthetic nanocarriers and therapeutic macromolecules for reduced or enhanced pharmacodynamic effects.
MX341076B (en) Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments.
MY191358A (en) Triazolopyrazines as brd4 inhibitors for use in the treatment of cancer
BR112019011065A2 (en) methods for determining car cell dosage
EA201391033A1 (en) BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
MX366317B (en) Compositions and methods for treating chronic inflammation and inflammatory diseases.
EP3016715A4 (en) Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
EP2992881A4 (en) Pharmaceutical composition for inhibiting immune response through inducing differentiation into regulator t cells and promoting proliferation of regulator t cells
MY182222A (en) Pharmaceutical compositions and methods of use of 4-pregenen- 11?-17-21-triol-3,20-dione derivatives
EA201491613A1 (en) CATIONIC POLYMERS BASED ON GLYCOGEN
MX365403B (en) Peptides and methods of using same.
MX2015017959A (en) Compositions and methods for immunotherapy.
EP2968613A4 (en) Delivery of card protein as therapy for occular inflammation
NZ700274A (en) Anti-pdgf-c antibodies